April 16, 2019
Cato Research part of a "World-class Team" and serves as a Key Player in Ology Bioservices Development Programs PDF

April 3, 2019
Cato Research Appoints Life Sciences Leader And Innovator To Executive Chairman PDF

February 28, 2019
OncBioMune Announces Consulting Agreement with CATO Research LLC for Developing PGT, a Protein Drug Complex Targeting CD71 for Refractory Cancers PDF

November 28, 2018
Cato Research Partners with Water Street and JLL Partners to Continue Growth and Expansion PDF

April 21, 2018
Cato Research Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2018 PDF

March 23, 2018
Cato Research awarded "Best International Clinical Trial Services Provider 2018" PDF

January 2018

Lynda Sutton, principle and cofounder of Cato BioVentures, a family owned venture capital of Cato Holdings, was recently featured in BioWorld's article titled, "Alternative to traditional venture capital money could fill translational gaps" by Jennifer Boggs, for her panel discussion at this year's January RESI conference featuring Cato BioVentures' innovative investment approaches in the healthcare sector:

"Cato Bioventures, for instance, started investing in gene therapy in 2000. "We're finally seeing early results," said Lynda Sutton, principal and co-founder.

Launched in 1988 as the venture capital affiliate of Cato Holding, a privately held family fund, has built a portfolio of firms, including those developing therapeutics, medical devices and stem cell therapies. It invests in firms at all stages of development and across multiple therapeutic areas, and its funds have gone into both public and private firms. Cato Bioventures offers a two-pronged approach to its investments, said Sutton, who, like de Souza, is another pharma veteran. The first is to look for technology "that needs a home, bring it in and form a company around it," with the aim of getting it to a value inflection point. The second involves looking for companies with good management, promising technology and invest money and resources to complement drug development efforts."


October 2, 2017
Mallinckrodt plc (NYSE:MNK) today announced it has entered into a licensing agreement for development and commercialization of NeuroproteXeon's investigational, pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and functional outcomes for patients resuscitated after a cardiac arrest. PDF

April 29, 2017
Cato Research and Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2017 PDF

May 10, 2016
Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2016 PDF

May 05, 2016
Manufacturing has begun for Cancer Advances' Lead Product PDF

March 28, 2016
NeuroproteXeon Appoints Cato Research for Phase III Trials

NeuroproteXeon Appoints Cato Research for Phase III Trials

On January 29th Mervyn Maze, MB, ChB, Chief Medical Officer of NeuroproteXeon announced CATO Research of Durham, North Carolina as the Clinical Research Organization (CRO) administering the Company's Phase III trial. Dr. Maze indicated the selection reflects CATO's three decades of experience in international trial administration, their broad international scope, and the ease with which NP and CATO management interacted.

Present plans are for a nine country, approximately 30 sites, 1,300 patent trial, comparing hypothermia with hypothermia plus Xenon. The primary outcome will be survival from cardiac arrest. It is anticipated the trial will be complete in less than two years following FDA/ EMA approval of the Company's IND application.

CATO commences work with NP immediately. By the end of February, NP's draft protocol will be expanded and forwarded to the Trial Executive Committee. They will edit the protocol in March and submit it to the FDA for a Special Protocol Assessment later that month. This usually occurs within 45 days of submission. Following agreement with the Agency on trial design, the protocol will be incorporated in our Investigational New Drug Application.

The timing of the protocol assessment dovetails well with drug profiling and device development. The Praxair Drug Master File for cGMP Xenon, which we will reference, will be filed in March.

The tranche of additional toxicology tests requested by FDA will be completed and reported by June. Prototypes of both the clinical test device and consumable breathing circuit/ absorber will be available for validation and verification in mid-March. The devices will be ready for submission in early July.

The plan is anticipated to come together to allow device manufacture, site qualification and training in the fourth quarter and initial patient enrollment in January, 2017.



March 8, 2016
Cancer Advances attends PanCAN PDF